Actively Recruiting
Phase II Study of Oral Imlunestrant Combined With Abemaciclib for Patients With ER Breast Cancer and Minimal Residual Disease
Led by Jonsson Comprehensive Cancer Center · Updated on 2026-08-20
42
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of imlunestrant and abemaciclib in treating patients with estrogen receptor positive ER breast cancer who have minimal residual disease, meaning tumor cells remain detectable in the blood after prior treatment. This phase II trial focuses on how well this combination clears circulating tumor DNA, which may indicate treatment response. The study also assesses safety, distant recurrence-free survival, and explores biomarkers that could predict response to therapy. Participants receive oral abemaciclib twice daily and oral imlunestrant once daily in repeating 28-day cycles, for up to 12 cycles unless disease progresses or unacceptable side effects occur. Blood samples are collected regularly throughout the treatment to monitor tumor DNA levels. Radiologic scans may be performed as needed based on physician judgment. After treatment, participants have a follow-up visit 30 days later, then continue monitoring every 4 months for one year. During the study, participants undergo regular assessments including blood tests to measure circulating tumor DNA clearance and re-emergence, safety evaluations, and distant recurrence monitoring. The main outcome is the rate of tumor DNA clearance after 12 treatment cycles. The study team also tracks adverse events up to 30 days post-treatment. Total participation spans treatment plus one year of follow-up after completion.
CONDITIONS
Brief Title
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Research Team
R
Ruth Gonzalez
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here